MedTrace Logo

EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies

NCT02701907 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2022-09-07

No results posted yet for this study

Summary

Adult patients with metastatic or locally advanced solid malignancies (including but not limited to breast, cancer, lung adenocarcinoma or squamous cell carcinoma, colorectal cancer, ovarian cancer, renal clear cell cancer, skin cutaneous melanoma), presenting or having presented an exceptional and unexpected response to an antineoplastic targeted therapy.

Conditions

  • Metastatic Cancers

Interventions

OTHER

Blood sampling

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Charles Ferté, MD PhD · Gustave Roussy, Cancer Campus, Grand Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2021-04-17
Completion
2022-04-17

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02701907 on ClinicalTrials.gov